Related Experiment Video
Updated: May 14, 2026
07:50
Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Cysteamine: an old drug with new potential
Martine Besouw1, Rosalinde Masereeuw, Lambert van den Heuvel
1Department of Pediatric Nephrology, University Hospitals Leuven, Leuven, Belgium. martine.besouw@uzleuven.be
Drug Discovery Today
|February 19, 2013
Summary
Cysteamine, an amino thiol, is reviewed for its therapeutic applications beyond cystinosis. New formulations and ongoing trials explore its potential for neurodegenerative disorders and nonalcoholic fatty liver disease (NAFLD).
Area of Science:
- Biochemistry
- Pharmacology
- Medical Research
Background:
- Cysteamine (HSCH2CH2NH2) is an endogenous amino thiol derived from coenzyme A.
- Its primary therapeutic use has been in treating cystinosis by reducing lysosomal cystine accumulation.
- Existing research highlights cysteamine's diverse in vitro and in vivo applications.
Purpose of the Study:
- To comprehensively review the established and emerging applications of cysteamine.
- To provide an overview of current clinical trials investigating new indications for cysteamine.
- To discuss the impact of novel drug formulations on cysteamine's therapeutic reach.
Main Methods:
- Literature review of cysteamine's applications.
- Analysis of data from in vitro and in vivo studies.
- Summary of ongoing clinical trial information for new therapeutic areas.
Main Results:
- Cysteamine demonstrates utility beyond its primary indication in cystinosis.
- Emerging research suggests potential applications in neurodegenerative diseases and nonalcoholic fatty liver disease (NAFLD).
- A new enteric-coated formulation enhances patient compliance and broadens therapeutic possibilities.
Conclusions:
- Cysteamine possesses a wide range of therapeutic applications.
- Ongoing clinical trials are expanding its use into new disease areas.
- Improved drug delivery systems are poised to increase cysteamine's clinical significance.
Related Concept Videos
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
01:10Drugs that Destabilize Microtubules
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:28Urologic Endoscopic Procedure: Cystoscopic Examination
Meaning of Cystoscopic Examination:Cystoscopy is an essential diagnostic tool in urology that is used to assess the structure and function of the genitourinary system. It provides a direct view of the urethra, bladder, and, in some cases, the ureteral openings. This procedure helps detect structural abnormalities, infections, cancers, and blockages in the urinary tract. There are two types of cystoscopy:Flexible cystoscopy is commonly performed in outpatient settings due to its less invasive...